A股異動|佛慈制藥午後拉漲逾3%公司獨家品種和特色產品進入國家醫保目錄
格隆匯8月22日丨佛慈制藥(002644.SZ)午後直線拉昇,現報6.84元,漲3.32%,暫成交1374萬港元,最新總市值34.9億港元。佛慈制藥午間發佈公告稱,公司獨家品種舒肝消積丸兩個劑型(大蜜丸、水蜜丸)以及特色產品濟生橘核丸(濃縮丸)進入國家醫保目錄乙類範圍。將有利於擴大產品市場份額,對公司未來的經營業績產生積極影響。截至目前,公司共有215個品規產品進入國家醫保目錄,甲類範圍128個,乙類範圍87個。此外據悉,佛慈制藥曾於7月25日發中期業績公告指,期內營業收入約3.12億元,同比增長14.01%;歸屬於上市公司股東的淨利潤約4451.22萬元,同比增長5.01%;基本每股收益0.0872元。(行情來源:富途證券)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.